The NCI-MATCH trial included patients with BRAF V600E-positive solid tumours (excluding melanoma, thyroid carcinoma and colorectal carcinoma), while the paediatric trial included patients with refractory or recurrent low or high grade glioma. The gene discussed is BRAF; the disease is central nervous system cancer.